Strata Critical Medical, Inc. (SRTA) Form 10-Q — Aug 4, 2026
Strata Critical Medical reported significant revenue growth for the six months ended June 30, 2026, reaching $139.9 million, a 72.6% increase from the prior year period. This growth was driven primarily by the expansion of the Clinical segment following the acquisition of Keystone and three smaller acquisitions in 2026, alongside organic growth in the Logistics segment. Adjusted EBITDA improved substantially to $14.3 million compared to $2.9 million in the prior year, reflecting strong operational performance despite non-cash accounting impacts.
Key figures
- Eps
- -0.10
- Revenue
- 139,890,000
- Net Income
- -8,362,000
- Cash Position
- 16,317,000
- Revenue Growth
- 72.6%
- Adjusted EBITDA
- 14,297,000
- Amortization Of Intangible Assets
- 8,113,000
Price after filing
Close on the filing date to close N calendar days later (from $5.09). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.